← 返回

食管鳞状细胞癌中浆细胞 XBP1 过度激活通过先天免疫提示更差的生存

英文原题:Overactivation of XBP1 in plasma cells implies worse survival through innate immunity in esophageal squamous cell carcinoma.

查看英文原题

Overactivation of XBP1 in plasma cells implies worse survival through innate immunity in esophageal squamous cell carcinoma.

PubMed 2024/06/12(内容时间) Cancer Lett Q1 · IF 11.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

为了维持蛋白质稳态,X-box结合蛋白1(XBP1)在内质网(ER)应激下未折叠蛋白反应(UPR)激活后发生剪接。尽管靶向ER应激代表了一种有前景的治疗策略,但在细胞水平上对XBP1的全面理解以及XBP1与先天神经系统之间的联系仍然缺乏。

本研究分析了来自33种癌症类型的TCGA泛癌数据集、来自454例患者的scRNA泛癌数据集以及来自155对配对食管鳞状细胞癌(ESCC)患者的bulk RNA-seq数据集。为了应对ER应激,浆细胞在经历细菌感染和来自先天免疫系统的炎症信号后倾向于激活XBP1。浆细胞中XBP1高表达的患者具有更高的肿瘤分级和更差的生存。

然而,先天免疫系统的激活伴随浆细胞中XBP1表达增加与淋巴细胞比率升高相关,表明免疫反应更为强健。此外,XBP1激活似乎在转录水平上启动白细胞迁移。

我们的研究揭示,XBP1诱导的UPR可能介导ESCC中最佳获得性体液免疫反应与先天免疫之间的串扰。

展开英文摘要原文

To maintain protein homeostasis, X-box binding protein 1 (XBP1) undergoes splicing following the activation of the unfolded protein response (UPR) in response to endoplasmic reticulum (ER) stress. Although targeting ER stress represents a promising therapeutic strategy, a comprehensive understanding of XBP1 at the cellular level and the link between XBP1 and the innate nervous system is lacking.

Here, TCGA pancancer datasets from 33 cancer types, scRNA pancancer datasets from 454 patients and bulk RNA-seq datasets from 155 paired esophageal squamous cell carcinoma (ESCC) patients were analyzed. To cope with ER stress, plasma cells tend to activate XBP1 after undergoing bacterial infection and inflammatory signaling from the innate immune system. Patients with high XBP1 expression in their plasma cells have a higher tumor grade and worse survival.

However, activation of the innate immune system with increased XBP1 expression in plasma cells correlates with an increased lymphocyte ratio, indicative of a more robust immune response.

Moreover, XBP1 activation appears to initiate leukocyte migration at the transcriptional level.

Our study revealed that the XBP1-induced UPR could mediate the crosstalk between optimal acquired humoral immune responses and innate immunity in ESCC.

论文信息

作者
Yin Y、Wang Y、Yu X、Li Y、Zhao Y、Liu Z
第一作者单位
State Key Laboratory of Molecular Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.China
通讯作者单位
State Key Laboratory of Molecular Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. Electronic address: liuzh@cicams.ac.cn.China
文献类型
非美国政府资助研究
期刊
Cancer letters2024 Aug 10
原文标识
PubMed 38871246 · DOI 10.1016/j.canlet.2024.217045